ModifiedUnitedHealthcarePolicy CS015OH.F

Cardiovascular Disease Risk Tests (for Ohio Only)

Defines medical necessity and coverage stance for a range of cardiovascular risk tests (arterial compliance/waveform analysis, endothelial function/PAT, CIMT, advanced lipoprotein and multi-protein biomarker assays) for UnitedHealthcare community plan members in Ohio.

Policy Summary

PayerUnitedHealthcare

PolicyCardiovascular Disease Risk Tests (for Ohio Only)

Policy CodePolicy CS015OH.F

Change TypeRevisions to unproven/NMN listadded CPT 0541U

Effective DateSep 1, 2025

Next Review Date

Key ActionDocument prior authorization requirements and ensure documentation of clinical rationale when ordering advanced lipoprotein or multi-protein algorithmic tests.

SourceLink

POLICY UPDATE CHANGES

Revised list of unproven and not medically necessary services; added 'cardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins (apolipoproteins A1, C1, C2, C3, and C4), with algorithm and reported as a risk score'.

Added CPT code 0541U to Applicable Codes.

Updated Clinical Evidence and References sections to reflect the most current information.

OhioApplies only to

multipleUnproven tests

0541UAdded code

100,667

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

CIMT RCT participants

NLA/ESCLp(a) thresholds

Coverage Criteria and Policy Stance

inv-01: Unproven / Not Medically Necessary

Tests considered unproven and not medically necessary due to insufficient evidence of efficacy include:

Unproven tests listed: Arterial compliance testing using waveform analysis; endothelial function assessment using peripheral arterial tonometry (PAT) or brachial artery ultrasound as a prognostic indicator; multi-protein diagnostic biomarker panels (including aptamer-based microarray algorithms; 3-protein, 4-protein, and 7-protein panels as specified); cholesterol efflux capacity/LC-MS/MS quantitative measurement of five HDL-bound apolipoproteins with algorithm-reported risk score; advanced lipoprotein analyses listed where evidence is insufficient

These services are identified in the policy as unproven and not medically necessary.

inv-02: CIMT — evidence and coverage considerations

Summary of evidence-based coverage considerations

CIMT as risk assessment: Carotid intima-media thickness (CIMT) is associated with incident cardiovascular events but provides only modest incremental risk reclassification beyond traditional risk factors; coronary artery calcium (CAC) scoring generally provides superior risk discrimination.1 mm noted in some subgroup analyses

Multiple systematic reviews and meta-analyses report modest benefit or heterogeneity; clinical utility in altering management or improving outcomes has not been demonstrated.

inv-03: Advanced lipoprotein biomarkers — evidence and coverage considerations

Summary of evidence-based coverage considerations for advanced lipoprotein testing

Lp(a) measurement: Elevated lipoprotein(a) (Lp[a]) is consistently associated with increased risk of cardiovascular events in observational cohorts and meta-analyses, but its incremental value over conventional risk factors and impact on clinical outcomes is not established.50 mg/dL commonly used in studies

Heterogeneity in thresholds and populations; evidence supports association but not established clinical utility for routine testing

Lp-PLA2 measurement: Evidence for lipoprotein-associated phospholipase A2 (Lp-PLA2) is low-quality and inconsistent; no conclusions can be drawn regarding clinical utility of Lp-PLA2 alone or combined with traditional markers for risk assessment.

Additional well-designed trials are needed

Advanced lipoprotein panels and fractionation: Studies report inconsistent incremental benefit of advanced lipoprotein testing (apoB, particle number, NMR or high-resolution fractionation) over conventional lipid profiles, and replacement of total cholesterol/HDL-C with advanced parameters did not significantly improve risk prediction in large pooled analyses.

inv-04: General coverage stance for Lp-PLA2, multi-protein risk scores, and endothelial function testing

Covered only when evidence supports clinical utility to guide management (none demonstrated in reviewed studies); otherwise not supported for routine use.

Primary evidence-based conclusions: Current evidence does not demonstrate sufficient clinical utility for Lp-PLA2 measurements, multi-protein algorithmic risk scores, or endothelial function assessments (eg, PAT, brachial FMD) to guide management and improve patient outcomes.

Multiple systematic reviews, meta-analyses, and cohort studies report associations but no demonstrated benefit from integrating these tests into care pathways.

inv-05: Endothelial function testing (PAT/RHI) — evidence and recommendations

Evidence and recommendations around endothelial function testing are mixed; covered only with clear clinical rationale in select cases per payer policy.

evidence summary: Some observational studies report associations between PAT-derived indices (eg, reactive hyperemia index, LRHI) and risk factors or outcomes, and one study identified LRHI <0.4 as independently predictive of events; however multiple studies failed to show RHI predicts coronary plaque extent, CAC, or major adverse cardiovascular events (MACE), and overall clinical utility for routine risk stratification is unestablished.LRHI <0.4 cited as predictive in one study

Well-designed outcome studies demonstrating that PAT/RHI use changes management or improves outcomes are lacking.

inv-06: Advanced lipid and other risk marker testing (Lp[a], ApoB, Lp-PLA2, CIMT, advanced lipoprotein testing)

Professional society guidance supports selective measurement of certain markers in specific clinical contexts rather than routine screening.

when measurement may be reasonable: Measurement of Lp(a) or apolipoprotein B (ApoB) may be reasonable in adults with premature or unexplained ASCVD, a family history of premature ASCVD, very high baseline risk, or when traditional risk factors are inconclusive; CIMT may be considered to refine risk in selected patients per some societies; measures of arterial stiffness and peripheral flow-mediated dilation are not recommended for routine risk assessment.Lp(a) thresholds referenced by guidelines (eg, ≥50 mg/dL as risk-enhancing)

References include AACE/ACE, ACC/AHA, ESC/EAS, NLA; prioritize standard lipid panel and established risk calculators before advanced tests.

inv-07: Coverage Rationale / Policy stance — summary and recent revisions

Summary of policy stance and recent revisions

Policy-level determinations: The policy revision updates the list of tests considered unproven or not medically necessary (including the specified cholesterol efflux capacity LC-MS/MS HDL apolipoprotein panel) and adds CPT code 0541U to the Applicable Codes list. Guideline sources (eg, VA/DoD) cited recommend against routine use of additional risk markers when assessing cardiovascular risk.

Detailed coverage criteria and exclusions are described elsewhere in the full policy document and the Summary of Changes documents these operational updates.

Arterial compliance testing using waveform analysis and endothelial function assessment (for example, peripheral arterial tonometry [PAT] or brachial artery ultrasound) are listed in this policy as unproven and not medically necessary because available evidence is insufficient to demonstrate clinical utility for cardiovascular risk assessment or to change patient management.

Carotid intima-media thickness (CIMT) is associated with incident cardiovascular events but provides only modest incremental improvement in risk prediction beyond traditional factors; randomized-trial and cohort syntheses report small or clinically limited gains. Because coronary artery calcium (CAC) scoring generally offers superior discrimination and the impact of incorporating CIMT into care on clinical outcomes has not been demonstrated, routine CIMT screening for asymptomatic individuals is not supported by this policy.

Large pooled analyses show that replacing conventional lipid measures (total cholesterol and HDL-C) with alternative lipid parameters — including Lp-PLA2 or other advanced lipid markers — did not meaningfully improve cardiovascular risk prediction. Therefore substituting standard lipid testing with these other parameters for routine risk assessment is not supported.

Measures of arterial stiffness and peripheral flow-mediated dilation (including brachial FMD) are not recommended for routine cardiovascular risk assessment in asymptomatic adults. Guideline statements classify arterial stiffness measures performed outside research settings and peripheral endothelial function testing as having no demonstrated benefit for routine risk stratification, and the peer-reviewed literature lacks consistent evidence that such measures improve clinical management or outcomes.

Routine population screening for peripheral artery disease using the ankle-brachial index (ABI) and routine use of additional risk markers in asymptomatic populations are not supported due to insufficient evidence. Guideline statements (USPSTF; VA/DoD) and meta-analyses conclude that routine ABI or routine addition of extra biomarkers does not have demonstrated benefit in asymptomatic adults and therefore should not be performed routinely.

The policy revision adds a specific multi‑analyte HDL-related test to the list of services considered unproven: cholesterol efflux capacity measured by LC‑MS/MS with quantitative measurement of five HDL‑bound apolipoproteins (A1, C1, C2, C3, C4) reported via an algorithmic risk score. This test (described in the Summary of Changes) is therefore treated as not medically necessary under the updated policy.

Multi‑protein biomarker panels (including aptamer‑based proteomic assays and algorithm‑reported risk scores comprised of 3, 4, or 7 proteins) are considered unproven. The policy notes insufficient high-quality clinical evidence that these algorithmic multi‑protein tests alter clinical management or improve outcomes; therefore routine use is not supported.

Routine measurement of CIMT, Lp‑PLA2, or other advanced lipoprotein tests (including apoB and specialty lipoprotein fractionation) in asymptomatic individuals is discouraged when results are unlikely to change management. Evidence is inconsistent regarding incremental predictive value and there is no demonstrated improvement in patient outcomes to justify routine ordering.

Routine ordering of Lp‑PLA2 assays, multi‑protein blood tests that report an algorithmic risk score, and endothelial function assessments (PAT, brachial ultrasound/FMD) is discouraged because current evidence does not show these tests meaningfully guide therapy or improve clinical outcomes; use should be limited to research or select clinical contexts with documented rationale.

Peripheral arterial flow‑mediated dilation and measures of arterial stiffness are not supported for routine clinical use outside of research settings. Guideline recommendations and the literature conclude these assessments lack sufficient evidence of benefit for asymptomatic risk stratification and therefore are considered unsupported for routine practice.

The updated unproven/not medically necessary list explicitly includes tests such as the cholesterol efflux capacity LC‑MS/MS apolipoprotein panel (the five‑apolipoprotein HDL panel reported by algorithm), which the policy now lists as an example of services considered not medically necessary.

Applicable Codes and Thresholds

Applicable PLA/CPT/Proprietary codesmixed

0019M	Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations.
0052U	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation.
0308U	Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]), with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive CAD.
0309U	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event.
0377U	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables).
0415U	Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLig, and HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS.
0541U	Cardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins (apolipoproteins A1, C1, C2, C3, and C4), serum, algorithm reported as prediction of coronary artery disease (pCAD) score.
83695	Lipoprotein (a).
83698

Applicable laboratory & vascular procedure codesmixed

83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2).
83701	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (e.g., electrophoresis, ultracentrifugation).
83704	Lipoprotein, blood; quantitation of lipoprotein particle number(s) (e.g., by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed.
93050	Arterial pressure waveform analysis for assessment of central arterial pressures includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive.
93799	Unlisted cardiovascular service or procedure.
93895	Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral.
93998	Unlisted noninvasive vascular diagnostic study.

Applicable CPT Codes (added)CPT

0541U

noted as added to Applicable Codes in Summary of Changes

FDA product codes (device/test searches)mixed

DXN	FDA product code for non-invasive blood pressure measurement system products (search code)
IYO	FDA product code for B-mode ultrasound equipment used to measure CIMT
DFC	FDA product code for products used to measure lipoprotein(a)
NOE	FDA product code for Lp-PLA2 measurement products
JJX	FDA product code for Lp-PLA2 measurement products

FDA 510(k) clearances referencedmixed

K032519	EndoPAT 2000 510(k) clearance
K001852	PAT 1000 RD predicate device referenced in 510(k)
K122129	SphygmoCor XCEL System 510(k) clearance referenced
K070795	SphygmoCor CVMS predicate clearance referenced

cfPWV cut-off considered in pooled analysis

cfPWV cut-offs consideredClosest cut-off points ~10.7–11.5 m/s used in pooled cfPWV analysis

cfPWV performance summaryPooled HSROC AUC ~0.75–0.78 for cardiovascular and all-cause mortality

Study limitations notedPublication bias, small sample sizes, population and measurement heterogeneity acknowledged

CIMT cutoff — 1 mm referenced

CIMT diagnostic cutoff referenced1 mm identified as a more accurate diagnostic criterion for CAD in subgroup analysis

CIMT sensitivity/specificity

Provider Guidance, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization May Be Required

Prior authorization may be required for certain advanced or newly added cardiovascular risk tests (including but not limited to CPT 0541U and other algorithm-based multi‑protein panels). Providers should verify plan-specific PA requirements before ordering.

May affect codes: 0541U, 0019M, 0052U, 0308U, 0309U, 0377U, 0415U, 0415U, 83695, 83698, 83701, 83704, 93799, 93998, 93050, 93895

Denial Risk

Denial Risk for Unproven Tests

Services listed as unproven in this policy (e.g., arterial compliance/waveform analysis, endothelial function assessment, multi‑protein algorithmic biomarker panels, certain HDL functionality assays) are considered not medically necessary and may be denied.

Denial triggers include tests lacking demonstrated clinical utility or peer‑reviewed evidence to change management.
Commonly affected services: PAT, brachial artery ultrasound endothelial testing, aptamer-based proteomic risk panels, HDL reverse cholesterol transport panels.

Background and Scope

Cardiovascular disease is a leading cause of morbidity and mortality. Noninvasive risk markers — including arterial compliance/waveform analysis, endothelial function testing (PAT/FMD), carotid intima‑media thickness (CIMT), and advanced lipoprotein or multi‑protein biomarker assays — have been proposed to detect subclinical atherosclerosis or refine risk estimates. However, for many of these tests the evidence is limited or inconsistent, and the policy reflects a cautious approach: prioritize established risk assessment (standard lipid panels and validated risk calculators) and reserve advanced or investigational tests for situations where documented clinical rationale and evidence demonstrate they will alter management.

Definitions

Peripheral arterial tonometry (PAT) definition

DefinitionPeripheral arterial tonometry (PAT) records finger arterial pulse wave amplitude in response to reactive hyperemia to assess endothelial function

Measured indicesProduces indices such as reactive hyperemia index (RHI) and augmentation indices derived from digital pulse amplitude changes

Clinical use noteUsed as a noninvasive adjunct to risk assessment; studies show mixed associations with coronary plaque and events

Carotid intima-media thickness (CIMT) definition

DefinitionCarotid intima-media thickness (CIMT) is an ultrasound measurement of combined intima and media thickness of the carotid artery wall as a surrogate marker of atherosclerotic burden

Measurement methodObtained via high-resolution B-mode ultrasound with computer-assisted measurement of arterial wall layers

Policy Revision History

Policy Summary

PayerUnitedHealthcare

PolicyCardiovascular Disease Risk Tests (for Ohio Only)

Policy CodePolicy CS015OH.F

Change TypeRevisions to unproven/NMN listadded CPT 0541U

Effective DateSep 1, 2025

Next Review Date

Key ActionDocument prior authorization requirements and ensure documentation of clinical rationale when ordering advanced lipoprotein or multi-protein algorithmic tests.

SourceLink

On This Page

Standardization and patient-selection criteria are lacking; further prospective research required

Pooled sensitivity ~0.68 and specificity ~0.70; AUC ~0.74

Clinical utility caveatAnalyses did not address whether CIMT improves patient outcomes or changes management

Lp(a) abnormal threshold — 50 mg/dL

Lp(a) abnormal threshold used in ATTICA50 mg/dL used to define abnormal Lp(a) status

ATTICA cohort findingsTen-year CVD event rate: 14% for Lp(a) <50 mg/dL vs 24% for Lp(a) ≥50 mg/dL

Interpretation noteAssociation observed but incremental clinical utility for decision-making not established

Lp(a) risk thresholds (nmol/L and mg/dL categories)

Lp(a) risk categories (NLA) — Low< 75 nmol/L (~30 mg/dL)

Lp(a) risk categories — Intermediate75–125 nmol/L (30–50 mg/dL)

Lp(a) risk categories — High/Very High≥ 125 nmol/L (≥50 mg/dL); very high >180 mg/dL (>430 nmol/L)

hs-CRP threshold cited

hs-CRP risk-enhancing thresholdElevated high-sensitivity CRP defined as ≥ 2.0 mg/L

ContextListed as a risk-enhancing factor in ACC/AHA primary prevention guidance

Use implicationMay inform clinician-patient risk discussion but not standalone routine screening test

Ankle-brachial index threshold

Ankle-Brachial Index (ABI) thresholdABI < 0.9 constitutes abnormal and a risk factor

Guideline contextIdentified as a risk-enhancing factor in ACC/AHA guidance

Screening implicationRoutine ABI screening in asymptomatic adults not generally supported by guidelines

Triglyceride threshold (ACC/AHA)

Triglyceride threshold (ACC/AHA)Nonfasting triglycerides ≥ 175 mg/dL considered elevated

Role as risk-enhancerPersistent primary hypertriglyceridemia listed as risk-enhancing factor

Measurement noteMay prompt further evaluation (eg, apoB) but not a substitute for conventional risk assessment

Denial Risk

Lack of Demonstrated Clinical Utility

Many evaluated tests (CIMT, Lp(a), Lp‑PLA2, multi‑protein panels, endothelial function assays) lack demonstrated clinical utility showing improved patient outcomes or clear impact on management decisions. Requests may be questioned and require justification.

Clinical utility concerns cited for: CIMT, Lp(a), Lp‑PLA2, multi‑protein algorithmic tests, endothelial function assessment.

Denial Risk

Use of Lp‑PLA2 Testing Lacks Established Utility

Lp‑PLA2 testing (alone or combined with traditional biomarkers) currently has insufficient high‑quality evidence to establish clinical utility for routine cardiovascular risk assessment. Additional well‑designed trials are needed. Orders may be subject to review.

Affected code: 83698 (Lp‑PLA2)

Documentation Required

Multi‑Protein Panels — Documentation and Evidence Concerns

Multi‑protein blood tests reported as an algorithmic risk score lack sufficient peer‑reviewed evidence of clinical utility. When performed, document the algorithm used, individual biomarkers measured, and how results will change management.

Document: list of biomarkers, algorithm name/version, interpretation, intended clinical action.
Examples of algorithmic tests: 0019M, 0308U, 0309U, 0415U, 0415U, 0541U.

Denial Risk

Denial Triggers from Guideline Insufficiency

Guideline bodies (USPSTF, VA/DoD, ADA) do not support routine use of many additional risk markers for general risk stratification; absence of guideline support may trigger coverage denials for screening in asymptomatic, low‑risk patients.

Examples: routine ABI screening, routine additional biomarkers beyond standard lipid panels and validated risk calculators.

Denial Risk

Denial Risk for Newly Listed Unproven/NMN Services

Services added to the unproven/not medically necessary list (including some novel multi‑marker and NMN services such as HDL reverse cholesterol transport panels) carry increased denial risk. Providers should consider alternative, guideline‑recommended assessments first.

Newly added CPTs (e.g., 0541U) are specifically listed as unproven and may be denied.
Consider conventional risk assessment prior to ordering advanced or experimental tests.

Documentation Required

Claim Documentation Note

When submitting claims for advanced cardiovascular risk tests, include detailed documentation: indication, test ordered (including CPT/Loinc when available), algorithm name/version, biomarkers measured, and how results influenced care. Reference Applicable Codes when filing claims.

Include: diagnosis linkage, medical necessity rationale, lab/regulatory compliance (CLIA), and any prior authorization approval.
Reference codes listed in Applicable Codes section.

Documentation Required

Document Rationale for CIMT Testing

If ordering carotid intima‑media thickness (CIMT), document clinical indication, baseline risk, rationale for CIMT over other imaging (e.g., CAC), and how the result will alter management; consider prior authorization where applicable.

Documentation should include: indication, baseline 10‑year risk estimate, reason for CIMT, and planned management changes based on result.

Documentation Required

Documentation When Using Multi‑Marker Panels or Algorithms

When multi‑marker panels or algorithmic tests are used, document the specific biomarkers, the algorithm or score used (including version), intended clinical decision pathway, and supporting literature or rationale for use.

Provide algorithm name/version, biomarkers measured, intended clinical action, and any validation studies supporting use.

Note

Laboratory and Regulatory Notes

Ensure laboratory testing complies with regulatory and quality requirements (e.g., CLIA). FDA device clearances are informational only and do not alone establish coverage. Maintain records of laboratory CLIA certification and device information when applicable.

Advanced lipoprotein analyses and other specialized assays must be performed in CLIA‑certified labs.
FDA clearance: informational — check product codes (e.g., DXN, IYO, DFC, NOE, JJX) for device details.

Documentation Required

Coverage Decision Documentation

Coverage decisions are determined by federal, state (Ohio Administrative Code), or contractual plan requirements. In case of conflict, those requirements govern. Document how the requested test meets applicable contractual/federal/state criteria.

Reference applicable federal/state/contractual requirements (OAC) when requesting coverage or appealing denials.
This policy is informational; final coverage depends on the member's benefit plan terms.

Note

Conventional Risk Assessment First; No Therapeutic Sequencing Specified

No therapeutic sequencing or step‑therapy requirements are specified for biomarker testing in this section. Use conventional risk assessment (standard lipid panel and validated risk calculators) before ordering advanced tests.

Prioritize: fasting lipid panel, blood pressure, smoking status, diabetes assessment, validated risk calculators (e.g., pooled cohort equations) before advanced testing.

Documentation Required

Use of Risk Markers Prior to Advanced Therapy

When considering advanced or novel risk markers to guide use of newer therapies, document objective risk stratification and rationale linking the marker to the intended therapeutic decision.

Document how the marker changes eligibility for advanced lipid‑lowering therapies or alters management beyond standard risk assessment.

Clinical guidanceSome societies consider CIMT useful to refine risk in select patients but guidelines vary and routine use is not broadly recommended

Multi-protein biomarker panels definition

DefinitionMulti-protein biomarker panels measure combinations of protein analytes and apply an algorithm to report a risk score for CAD/ACS or major adverse cardiac events

Examples in policyDescribed panels include 3-protein, 4-protein, and 5- or 7-protein algorithms and aptamer-based proteomic assays (eg, HART tests; aptamer microarray codes referenced)

Evidence caveatSystematic reviews report lack of demonstrated clinical utility and inconsistent evidence for improving outcomes

Carotid Intima-Media Thickness (CIMT) definition (alternate)

Definition (alternate)CIMT is the ultrasound measurement of carotid artery intima and media thickness used as a subclinical atherosclerosis marker

Diagnostic performance noteMeta-analyses show modest sensitivity/specificity for CAD; subgroup cutoff of 1 mm had improved AUC

Implementation noteProcedure is operator-dependent and incremental clinical utility for altering management is unproven

Lipoprotein(a) (Lp[a]) definition

DefinitionLipoprotein(a) (Lp(a)) is an LDL-like particle containing apolipoprotein(a) associated with increased cardiovascular risk

Clinical contextLp(a) is largely genetically determined and considered a risk-enhancing factor by multiple societies

Threshold variabilityStudies and guidelines reference multiple thresholds; typical values include 50 mg/dL and nmol/L categories per NLA/ESC

Lipoprotein-associated phospholipase A2 (Lp-PLA2) definition

DefinitionLipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme associated with vascular inflammation investigated as a biomarker for CHD and stroke risk

Clinical utilityEvidence is low-quality and inconsistent; clinical utility for routine risk assessment not established

Measurement modesReported as mass or activity in studies, with variable associations observed

Lp-PLA2 definition (mass/activity)

Measurement formsLp-PLA2 can be measured as mass or enzymatic activity; studies report heterogeneous methods and results

Evidence summaryGiven low-quality and inconsistent evidence, no definitive clinical role for mass vs activity measurement is established

Research needAdditional well-designed trials needed to determine whether Lp-PLA2 (mass or activity) adds useful risk stratification

Peripheral arterial tonometry (PAT) definition (indices like RHI)

PAT definition with indicesPeripheral arterial tonometry (PAT) is a fingertip-based noninvasive method to assess microvascular endothelial function producing indices such as reactive hyperemia index (RHI) and natural log RHI (LRHI)

Clinical findingsSome studies reported LRHI <0.4 predictive of events, but overall associations with plaque, CAC, and MACE are inconsistent

Intended useUsed as an adjunctive tool; not established for routine population screening

Cholesterol efflux capacity (CEC) definition

DefinitionCholesterol efflux capacity (CEC) quantifies HDL's ability to remove cholesterol from macrophages as a functional HDL measure

Association evidenceSystematic reviews report lower CEC in CAD cases and inverse dose-response with CAD risk, but inconsistent links to cardiovascular mortality

LimitationsAssay variability and lack of standardized cutoffs limit clinical application; incremental utility unproven

RHI / PAT definition

RHI/PAT definitionReactive hyperemia index (RHI) from peripheral arterial tonometry measures digital pulse amplitude change after induced reactive hyperemia to assess endothelial function

Indices describedIncludes RHI and LRHI; specific LRHI threshold (<0.4) reported as predictive in one multivariate analysis

Clinical relevanceStudies show mixed predictive value for coronary plaque extent, CAC, and MACEs

Lp(a) definition with thresholds noted

Lp(a) definition with thresholdsLp(a) is an LDL-like particle with apo(a); guideline-referenced thresholds include ≥50 mg/dL (≈125 nmol/L) as high and >180 mg/dL (>430 nmol/L) as very high

Guideline recommendationESC/EAS recommends measuring Lp(a) at least once to identify very high inherited levels (>180 mg/dL)

Clinical implicationElevated Lp(a) may warrant earlier or more intensive risk-factor management despite limited evidence on outcome impact of measurement alone

CIMT definition (society positions)

CIMT society positionsAACE states CIMT may be considered to refine risk in select patients; ACC/AHA does not recommend routine CIMT measurement for initial risk assessment

Guideline variabilityProfessional society guidance varies; CIMT may be selectively useful but is not universally endorsed for routine screening

Implementation noteConsider CIMT only when it will change management and document rationale due to modest incremental value

CIMT procedure note — ultrasound measurement not FDA-approved but equipment regulated

Procedure vs device regulationCIMT measurement using B-mode ultrasound is a procedure and not subject to FDA approval; ultrasound equipment is regulated by FDA

CLIA/quality noteAdvanced lipoprotein analyses must meet CLIA quality standards; device regulatory information is informational only

Reference for device searchesFDA product code IYO referenced for B-mode ultrasound equipment searches

EndoPAT 2000 device note (FDA 510[k] clearance K032519)

EndoPAT 2000 clearanceEndoPAT 2000 received FDA 510(k) clearance K032519 (Nov 12, 2003) as a noninvasive diagnostic aid for coronary artery endothelial dysfunction

Intended use per clearanceIndicated for patients with signs/symptoms of ischemic heart disease indicated for coronary angiography but without obstructive CAD; not for general population screening

Predicate devicesPredicate device listed: PAT 1000 RD (K001852); other related clearances include SphygmoCor XCEL (K122129)